Kura Oncology, Inc. (KURA) bonds
KURANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 1/30
$7.34−0.15 (-2.00%)
Close on Nov 18, 2026Market cap $652.97MP/E –Yield –
Debt
Borrowings on the balance sheet, Sep 30, 2026
Total debt
$9.83M
$8.53M due within a year
Net debt
-$48.10M
After $57.94M of cash
Implied interest rate
15.72%
FY2025 interest ÷ average debt
Interest coverage
-200.8×
FY2025 operating income ÷ interest
Total debt by fiscal year
Long-term plus current debt, USD
When the debt comes due
Principal repayments of long-term debt by fiscal year, as scheduled at Dec 31, 2024
From the debt maturity table in the annual report (filing). “Later” is everything due after year five.
Notes and loans outstanding
As tagged in Kura Oncology's 10-K for the period ended Dec 31, 2025
Kura Oncology's filings do not break debt down by note
The debt footnote in the annual report has no machine-readable detail for individual notes, so coupons and maturities cannot be listed. The repayment schedule above comes from the same report.
Credit facilities
Revolving credit lines and other committed borrowing capacity
| Facility | Size | Expires |
|---|---|---|
| Loan and Security Agreement | $125.00M | Nov 2, 2027 |
| Loan and Security Agreement | $10.00M | – |
| Loan and Security Agreement | $25.00M | – |
See a number that looks wrong?